| Title | Current status and perspectives on vaccine development against dengue virus infection |
|---|---|
| Author | Jisang Park1,2, Ju Kim3, and Yong-Suk Jang1,2,3* |
| Address | 1Department of Bioactive Material Sciences and the Research Center of Bioactive Materials, Jeonbuk National University, Jeonju 54896, Republic of Korea, 2Innovative Research and Education Center for Integrated Bioactive Materials, Jeonbuk National University, Jeonju 54896, Republic of Korea, 3Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Jeonbuk National University, Jeonju 54896, Republic of Korea |
| Bibliography | Journal of Microbiology, 60(3),247-254, 2022, |
| DOI | 10.1007/s12275-022-1625-y |
| Key Words | antibody-dependent enhancement, antigen, dengue virus, envelope, vaccine |
| Abstract | Dengue virus (DENV) consists of four serotypes in the family Flaviviridae and is a causative agent of dengue fever, dengue hemorrhagic fever, and dengue shock syndrome. DENV is transmitted by mosquitoes, Aedes aegypti and A. albopictus, and is mainly observed in areas where vector mosquitoes live. The number of dengue cases reported by the World Health Organization increased more than 8-fold over the last two decades from 505,430 in 2000 to over 2.4 million in 2010 to 5.2 million in 2019. Although vaccine is the most effective method against DENV, only one commercialized vaccine exists, and it cannot be administered to children under 9 years of age. Currently, many researchers are working to resolve the various problems hindering the development of effective dengue vaccines; understanding of the viral antigen configuration would provide insight into the development of effective vaccines against DENV infection. In this review, the current status and perspectives on effective vaccine development for DENV are examined. In addition, a plausible direction for effective vaccine development against DENV is suggested. |